CONCLUSION
In the present pilot study, we evaluated the potential of modulation of the IL-6 (colchicine), IL-17 (ixekizumab), and IL-2 signaling pathways to treat moderate to critical COVID-19 in hospitalized patients. Ixekizumab and IL-2 have been demonstrated to be safe but ineffective for COVID-19 treatment. Colchicine exhibited a statistically non-significant trend toward clinical improvement, but our findings need to be interpreted with caution because of our limited sample size and the differences observed in the baseline characteristics of the groups. 